1. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2015.113
Figure 3 Pharmacodynamic profile of switching from clopidogrel to prasugrel therapy: the SWAP study
Figure 3| Pharmacodynamic profile of switching from clopidogrel to prasugrel therapy: the SWAP study.45 Time course of platelet inhibition as measured with maximum platelet aggregation in response to 20 μmol/l ADP in patients with an acute coronary syndrome whose therapy was switched from clopidogrel to prasugrel. The results at time 0 are the baseline values obtained after a 2-week course of open-label clopidogrel treatment. 24 ± 2 h after the last clopidogrel dose was taken, patients were randomly assigned to one of the three study groups. *P < versus results with 75 mg MD of clopidogrel. ‡P < versus results with 10 mg MD of prasugrel. Abbreviations: LD, loading dose; MD, maintenance dose. Modified from Angiolillo, D. J. et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J. Am. Coll. Cardiol. 56 (13), 1017–1023 © (2010), with permission from Elsevier and the American College of Cardiology.
Modified from Angiolillo, D. J. et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasug­rel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J. Am. Coll. Cardiol. 56 (13), 1017–1023 © (2010), with permission from Elsevier and the American College of Cardiology
Rollini, F. et al. (2015) Switching P2Y12-receptor inhibitors in patients with coronary artery disease
Nat. Rev. Cardiol. doi: /nrcardio